Medicare Drug Pricing Reform and Policy Challenges: Navigating Legal Frameworks, Administrative Action, and Market Effects
Medicare Drug Pricing Reform and Policy Challenges: Navigating Legal Frameworks, Administrative Action, and Market Effects - Image 2

Medicare Drug Pricing Reform and Policy Challenges: Navigating Legal Frameworks, Administrative Action, and Market Effects

$170.00

Daniel Whitaker (Editor)

Series: Health Care in Transition; Government Procedures and Operations
BISAC: POL019000; MED036000; LAW046000

This book offers a comprehensive examination of recent reforms to Medicare drug pricing. It explores the multifaceted implications of federal drug price negotiation—an unprecedented shift in U.S. pharmaceutical policy.

Chapters address key legal and constitutional challenges to the negotiation program, including disputes under the Administrative Procedure Act and constitutional law. In parallel, the book analyzes the implementation of Medicare Part D reforms, the effects of rebates and premium stabilization efforts, and the evolving regulatory approach to GLP-1 and anti-obesity medications. Industry responses and market impacts are also critically assessed, offering insight into how pharmaceutical firms and Medicare stakeholders are adapting to the changing policy landscape.

somdn_product_page
ISBN: N/A Categories: , , , , , , , , ,

Table of Contents

Preface

Chapter 1. Medicare Drug Price Negotiation Under the Inflation Reduction Act: Industry Responses and Potential Effects
Kevin J. Hickey, Hannah-Alise Rogers and Laura A. Wreschnig

Chapter 2. Inflation Reduction Act of 2022: Initial Implementation of Medicare Drug Pricing Provisions
United States Government Accountability Office

Chapter 3. Constitutional Challenges to the Medicare Drug Price Negotiation Program
Hannah-Alise Rogers

Chapter 4. Administrative Procedure Act (APA) Challenges to the Medicare Drug Price Negotiation Program
Hannah-Alise Rogers

Chapter 5. Medicare Part D Prescription Drug Benefit
Suzanne M. Kirchhoff

Chapter 6. Medicare Part D: CMS Should Monitor Effects of Rebates on Drug Coverage and Spending
United States Government Accountability Office

Chapter 7. Medicare Part D Premium Stabilization Demonstration
Laura A. Wreschnig, Hannah-Alise Rogers and Michele L. Malloy

Chapter 8. Medicare Part D: Implementation of Beneficiary Premium Stabilization Demonstration
United States Government Accountability Office

Chapter 9. Medicare Coverage of GLP-1 Drugs
Laura A. Wreschnig

Chapter 10. Medicare Coverage of Anti-Obesity Medications
Assistant Secretary For Planning and Evaluation

Index

Publish with Nova Science Publishers

We publish over 800 titles annually by leading researchers from around the world. Submit a Book Proposal Now!